Six‐minute walk distance · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
QoL · pulmonary arterial hypertension
1 finding from 1 review
Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
PAP · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
Cardiac index · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
PVR · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
PAP · pulmonary arterial hypertension
1 finding from 1 review
Improvement in WHO functional class · people with pulmonary hypertension group 2 ‐ 4
Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).
1 finding from 1 review
Six‐minute walk distance · people with pulmonary hypertension group 2 ‐ 4
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with pulmonary hypertension group 2 ‐ 4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PASP · people with pulmonary hypertension group 2 ‐ 4
1 finding from 1 review
RAP · pulmonary arterial hypertension
1 finding from 1 review
Cardiac index · pulmonary arterial hypertension
1 finding from 1 review
PVR · pulmonary arterial hypertension
1 finding from 1 review
Improvement in WHO functional class · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).
1 finding from 1 review
Improvement in WHO functional class · pulmonary arterial hypertension
Prostacyclin probably leads to higher improvement in WHO functional class compared with control (moderate certainty).
1 finding from 1 review
Headache+ · pulmonary arterial hypertension
1 finding from 1 review